To see all protocols that comply with the WHO Essential Medicine List 

This resource provides guidance on how to safely undertake the procedure. Institutional practice may vary in accordance with local policy.

Only health care professionals who have attained competency (as per institutional guidelines) should perform this procedure.

Aseptic Non Touch Technique (ANTT®) used for this procedure is Standard-ANTT®.r

Standard-ANTT® is a framework and management approach for relatively simple and shorter invasive procedures. The aim is to maintain asepsis of all Key-Parts using standard precautions (e.g. hand hygiene and non-sterile gloves), a General Aseptic Field (e.g. decontaminated and disinfected procedure tray) and Key-Part Protection by Micro-Critical Aseptic Fields (e.g. sterile caps on syringe tip, inside of recently opened sterile packaging) and non-touch technique.

 Related eLearning:
- Central venous access devices
- Anti-cancer Drug Administration Course (ADAC)
Administration of anti-cancer drugs - IV (video)

This document provides information on the safe administration of intravenous anti-cancer drugs. Only healthcare professionals who have attained competency in central venous access device (CVAD) management, and the safe administration, handling and waste management of hazardous drugs (as per institutional guidelines) should perform this procedure.

This procedure should be read in conjunction with the Safe handling of hazardous drugs document and the Safe administration of anti-cancer drugs document.

Note: Vesicant drugs should always be administered first. Ensure CVAD is patent and monitor for signs of extravasation throughout vesicant administration.

This document reflects what is currently regarded as safe practice. While every effort has been made to ensure the accuracy of the content at the time of publication, the Cancer Institute NSW does not accept any liability, with respect to loss, damage, injury or expense arising from any such errors or omission in the contents of this work. Any reference throughout the document to specific pharmaceuticals and/or medical products as examples does not imply endorsement of any of these products. While eviQ endeavours to link to reliable sources that provide accurate information, eviQ and the Cancer Institute NSW do not endorse or accept responsibility for the accuracy, currency, reliability or correctness of the content of linked external information source. Use is subject to eviQ’s disclaimer available at www.eviQ.org.au

Send feedback for this page


First approved:
Last reviewed:
Review due:

The currency of this information is guaranteed only up until the date of printing, for any updates please check:

https://www.eviq.org.au/p/1127

29 Mar 2024